216 related articles for article (PubMed ID: 30350477)
1. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
Hövelmann U; Olsen MB; Mouritzen U; Lamers D; Kronshage B; Heise T
Diabetes Obes Metab; 2019 Mar; 21(3):601-610. PubMed ID: 30350477
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
[TBL] [Abstract][Full Text] [Related]
3. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.
Battelino T; Tehranchi R; Bailey T; Dovc K; Melgaard A; Yager Stone J; Woerner S; von dem Berge T; DiMeglio L; Danne T
Pediatr Diabetes; 2021 Aug; 22(5):734-741. PubMed ID: 33934456
[TBL] [Abstract][Full Text] [Related]
4. Dasiglucagon: an effective medicine for severe hypoglycemia.
Xu B; Tang G; Chen Z
Eur J Clin Pharmacol; 2021 Dec; 77(12):1783-1790. PubMed ID: 34223944
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
[TBL] [Abstract][Full Text] [Related]
6. Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.
Bailey TS; Willard J; Klaff LJ; Yager Stone J; Melgaard A; Tehranchi R
Diabetes Obes Metab; 2021 Oct; 23(10):2329-2335. PubMed ID: 34169625
[TBL] [Abstract][Full Text] [Related]
7. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
[TBL] [Abstract][Full Text] [Related]
8. Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes.
Li S; Hu Y; Tan X; Wang D; Hu J; Zou P; Wang L
Expert Opin Pharmacother; 2020 Aug; 21(11):1311-1318. PubMed ID: 32267182
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study.
Laugesen C; Ranjan AG; Schmidt S; Nørgaard K
Diabetes Care; 2022 Jun; 45(6):1391-1399. PubMed ID: 35475907
[TBL] [Abstract][Full Text] [Related]
10. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
[TBL] [Abstract][Full Text] [Related]
11. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
Pieber TR; Aronson R; Hövelmann U; Willard J; Plum-Mörschel L; Knudsen KM; Bandak B; Tehranchi R
Diabetes Care; 2021 Jun; 44(6):1361-1367. PubMed ID: 35239971
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
[TBL] [Abstract][Full Text] [Related]
13. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
[TBL] [Abstract][Full Text] [Related]
15. Dasiglucagon: First Approval.
Blair HA
Drugs; 2021 Jun; 81(9):1115-1120. PubMed ID: 34047955
[TBL] [Abstract][Full Text] [Related]
16. Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.
Ranjan A; Nørgaard K; Tetzschner R; Steineck IIK; Clausen TR; Holst JJ; Madsbad S; Schmidt S
Diabetes Care; 2018 Apr; 41(4):797-806. PubMed ID: 29358493
[TBL] [Abstract][Full Text] [Related]
17. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.
Wilson LM; Jacobs PG; Ramsey KL; Resalat N; Reddy R; Branigan D; Leitschuh J; Gabo V; Guillot F; Senf B; El Youssef J; Steineck IIK; Tyler NS; Castle JR
Diabetes Care; 2020 Nov; 43(11):2721-2729. PubMed ID: 32907828
[TBL] [Abstract][Full Text] [Related]
18. Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial.
Laugesen C; Ranjan AG; Schmidt S; Nørgaard K
Diabetologia; 2023 Jul; 66(7):1208-1217. PubMed ID: 37037948
[TBL] [Abstract][Full Text] [Related]
19. Dasiglucagon for treating severe hypoglycemia in patients with diabetes.
Ju Y; Zhang D; Yang J
Expert Rev Clin Pharmacol; 2022 Jul; 15(7):799-803. PubMed ID: 35848442
[TBL] [Abstract][Full Text] [Related]
20. Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus.
Stenninger E; Aman J
Diabetologia; 1993 Oct; 36(10):931-5. PubMed ID: 8243872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
